Performance
This page provides an overview of the performance of the Aescap Life Sciences and the Aescap Genetics fund. The historical NAVs of both funds can be found here.
Data below per April 30, 2025
- Net IRR since inception between 4,5 – 23%.
- Current net IRR is 4,5%.
- This despite a sharp fall in biotech share prices due to the Corona pandemic:
- Clinical trials halted
- Medicine development delayed
- As a result, little news & little M&A
- Aescap Life Sciences has outperformed the largest biotech ETF (IBB: iShares Biotech ETF).
Net IRR*
4,6%
2025
-15,5%
2024
13,2%
2023
-1,1%
2022
-14,4%
2021
-14,5%
2020
-3,0%
2019
30,0%
2018
46,9%
2017
4,7%
2016
12,2%
Since Start
50,8%
*Start of the fund on 28-03-2016
Net Performance Aescap Life Sciences as of
- Launched in 2021
- Suffered a lot of downtime in clinical trials during the Covid-19 pandemic and its aftermath.
- However, the companies in the fund are doing very well.
- Genetics companies are targeting the cause of disease with their medicines and are therefore seen as the future winners in biotech.
- Aescap Genetics has outperformed its benchmark, the J.P. Morgan Genetic Therapies Fund in EUR.
*Net IRR
-19,7%
2025
-33,0%
2024
-11,1%
2023
-1,4%
2022
-0,1%
Since Start
-41,4%
*Start of the fund on 19-01-2022
